1. Home
  2. WAFD vs BEAM Comparison

WAFD vs BEAM Comparison

Compare WAFD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WaFd Inc.

WAFD

WaFd Inc.

HOLD

Current Price

$33.31

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$26.70

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAFD
BEAM
Founded
1917
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WAFD
BEAM
Price
$33.31
$26.70
Analyst Decision
Hold
Strong Buy
Analyst Count
5
12
Target Price
$31.40
$48.09
AVG Volume (30 Days)
834.0K
2.0M
Earning Date
01-15-2026
11-04-2025
Dividend Yield
3.28%
N/A
EPS Growth
5.31
N/A
EPS
2.63
N/A
Revenue
$717,732,000.00
$55,701,000.00
Revenue This Year
$8.66
N/A
Revenue Next Year
$4.77
$26.52
P/E Ratio
$12.51
N/A
Revenue Growth
1.95
N/A
52 Week Low
$23.75
$13.53
52 Week High
$36.41
$35.25

Technical Indicators

Market Signals
Indicator
WAFD
BEAM
Relative Strength Index (RSI) 66.87 56.13
Support Level $32.70 $25.86
Resistance Level $33.65 $28.28
Average True Range (ATR) 0.68 1.63
MACD 0.07 0.25
Stochastic Oscillator 79.82 58.35

Price Performance

Historical Comparison
WAFD
BEAM

About WAFD WaFd Inc.

WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: